DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
|
Citation:
|
DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
|
DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
|
Citation:
|
DONG Xiao-rong, WANG Qian-yu. Efficacy of Nivolumab plus Ipilimumab as First-Line Treatment in Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 43-48. DOI: 10.12019/j.issn.1671-5144.2020.01.010
|
DownLoad: